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Risk Prediction in Cardiogenic Shock: Current State of
Knowledge, Challenges and Opportunities
SANJOG KALRA, MD, MSC,1 LAUREN S. RANARD, MD,2 SEHRISH MEMON, MD,3 PRASHANT RAO, MD,4
A. RESHAD GARAN, MD,4 AMIRALI MASOUMI, MD,2 WILLIAM O’NEILL, MD,5 NAVIN K. KAPUR, MD,6
DIMITRI KARMPALIOTIS, MD, PhD,2,7 JUSTIN A. FRIED, MD,2 AND DANIEL BURKHOFF, MD, PhD7
Toronto, Canada; New York,, and New York, New York; Philadelphia, Pennsylvania; Boston, Masschusetts; Detroit, Michigan; and Boston, Massachusetts

ABSTRACT
Cardiogenic shock (CS) is a condition associated with high mortality rates in which prognostication is
uncertain for a variety of reasons, including its myriad causes, its rapidly evolving clinical course and the
plethora of established and emerging therapies for the condition. A number of validated risk scores are
available for CS prognostication; however, many of these are tedious to use, are designed for application in
a variety of populations and fail to incorporate contemporary hemodynamic parameters and contemporary
mechanical circulatory support interventions that can affect outcomes. It is important to separate patients
with CS who may recover with conservative pharmacological therapies from those in who may require
advanced therapies to survive; it is equally important to identify quickly those who will succumb despite
any therapy. An ideal risk-prediction model would balance incorporation of key hemodynamic parameters
while still allowing dynamic use in multiple scenarios, from aiding with early decision making to device
weaning. Herein, we discuss currently available CS risk scores, perform a detailed analysis of the variables
in each of these scores that are most predictive of CS outcomes and explore a framework for the development of novel risk scores that consider emerging therapies and paradigms for this challenging clinical
entity. (J Cardiac Fail 2021;27:1099 1110)
Key Words: Cardiogenic shock, risk score, acute myocardial infarction, mechanical circulatory support.

the Killip classification in 19673 and the most recent being
the Society for Coronary Angiography and Intervention
(SCAI) classification of CS introduced in 2019.4 Although
thoughtfully derived, each individual risk score is challenged by 1 or more systematic limitations that restrict their
applicability and use at the bedside.
Herein, we summarize currently published risk scores
that aim to prognosticate CS outcome once a diagnosis of
CS has been made. Through a detailed, variable-level comparison, we also identify the most common and powerfully
predictive clinical components composing these scores.
Finally, we discuss why so many scores have been developed and why their use has been limited, if not unsuccessful, and we discuss the characteristics of an “ideal CS risk
score” and identify opportunities for future model development that will optimize both the predictive accuracy and the
application of CS therapies.

Although the precise incidence of cardiogenic shock (CS)
is uncertain, admissions to intensive care units (ICUs) due
to CS have doubled over the past 15 years.1,2 The rise in CS
prevalence has, in part, driven therapeutic innovation in the
management of CS and its underlying causes. Despite novel
treatment strategies, however, universal models to predict
outcomes and, importantly, optimal therapeutic choices,
remain elusive. In all, 30 CS outcome-prediction scores
have been developed over the past 5 decades, the first being
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Risk-Score Identification Methodology

Although not a formal review as would be done for a
meta-analysis, the CS risk scores explored herein were systematically identified using a PubMed/OVID/Medline
search using the following key words: cardiogenic shock
and risk score. Search results were narrowed to articles in
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English and were reviewed by the senior author (DB) to
identify published CS risk scores for review. The reference
sections of identified manuscripts were then further
reviewed to locate any scores not identified through the
search strategy above (LSR).
Cardiogenic Shock Risk Scores: Current State of
Knowledge
The most common cause of CS is acute myocardial
infarction (AMI), complicating nearly 10% of ST-segment
elevation myocardial infarction (STEMI) and 2.5% of nonST-segment elevation myocardial infarction (NSTEMI)
presentations.5,6 Despite the mortality benefits of routine
and timely primary percutaneous coronary intervention
(PCI) for both AMI7 and AMI complicated by CS,8 the
development of CS still portends a poor prognosis; in-hospital mortality for AMI-mediated CS (AMI-CS) is between
27% and 51%.6,8 13
Aside from AMI, however, multiple other disease states
can result in CS. They include end-stage cardiomyopathy,
myocarditis, cardiac tamponade, severe valvular heart disease, and arrhythmias.14 Additionally, CS may occur
through a variety of cardiovascular insults associated with
cardiac surgery. Clearly, the causes, management and
responsiveness to therapeutic interventions for each of these
scenarios vary greatly. Unfortunately, this level of granularity is often overlooked in registries and trial recruitments,
resulting in the study of widely disparate populations with
CS.
To date, most CS risk scores have been developed and
validated specifically in the setting of AMI-CS. Although
recent efforts have been made to analyze CS due to other
causes (eg, chronic heart failure),15 there are currently no
accurate and validated CS risk scores that are easily applicable at the bedside and, most important, generalizable to
all populations with CS. As such, currently available prognostic risk scores may be classified into 1 of 3 categories:
(1) those focused on critically ill patients requiring intensive
care; (2) those focused on patients with AMI-CS; and (3)
those pertinent to patients with CS who are supported by
mechanical support devices.
General Intensive-Care Risk Scores

Early CS risks scores were derived from patients in
ICUs who had heterogenous underlying conditions and
shock of varying causes; a detailed summary (including
component variables) of them can be found in Supplementary Table I.16 22
The clinical and biochemical variables included in these
scores are markedly disparate; physiological variables,
chronic health conditions and hospital admission diagnoses
are all included in the calculations. In unselected populations with shock, several have demonstrated clinically
meaningful mortality discrimination, with areas under the
curve (AUCs) of up to 0.83 on the Acute Physiology and
Chronic Health Evaluation (APACHE) II score.23 However,

when used in an AMI-CS setting, these scores predict mortality due to CS to a substantially lower degree,23 25 in part
because they were developed primarily in all comers admitted to a general ICU in whom cardiac failure was often a
secondary manifestation of the primary mode of shock. As
such, these scores lack applicability to contemporary cardiac patients in ICUs in whom cardiac failure is the primary
cause of their shock states. Further, the exhaustive inclusion
of multiple disparate variables inherent in many of these
scores render them both challenging to calculate and cumbersome to apply at the bedside.
Acute Myocardial Infarction-Associated Cardiogenic
Shock-Risk Scores

Since Killip’s work in the 1960s3 and Forrester, Diamond
and Swan’s report on the prognostic importance of cardiac
filling pressures,26 multiple risk scores have been developed
to prognosticate the outcomes of AMI, both with and without ST elevation (detailed summary in Supplementary
Table II).
Several of the AMI prognostication scores include CSrelated metrics, but many of studies from which they were
derived either excluded or did not specifically identify
patients with CS. Furthermore, in studies in which patients
with CS were included, both the definition of CS and the
primary outcomes assessed in each study varied, further
complicating the application of these scores to contemporary patients with CS. For example, in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for
Occluded Coronary Arteries (GUSTO-1) trial dataset,27 CS
was defined as systolic blood pressure (SBP) < 90 mmHg
for  1 hour, not responsive to fluids alone, signs of hypoperfusion or cardiac index < 2.2 liters/min/m2, and a pulmonary capillary wedge pressure higher than 18 mmHg. In
contrast, another contemporary risk score derived from the
Global Registry of Acute Coronary Events (GRACE) study
(and validated in a 16,000-patient sample from the GRACE
and GUSTO-1 cohorts), the Killip class IV definition was
used to identify patients in CS. Though the AUCs for both
studies were good for the prediction of their respective outcomes, the disparity in the CS definitions used underlie a
fundamental issue of CS risk-score development based on
clinical trial data in isolation.
Recent advancements in AMI treatment also limit the
validity and the applicability of AMI-related CS risk scores
to contemporary patients. Understandably, risk scores
developed during the period of thrombolytic therapy differ
fundamentally from those in the era of primary PCI for the
treatment of AMI, given the superiority of primary PCI
pharmacologic treatment alone in most patients with
STEMI.28 Furthermore, because many of the studies from
which AMI-CS prognostic scores were derived did not have
uniform approaches to revascularization (eg, some studies
limited the use of PCI only to the rescue setting), the use of
these data for the derivation of CS risk scores for today’s
patients with AIM-CS who are treated with timely primary
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PCI is fundamentally challenged.29 Finally, scores developed in the primary PCI era focused on prognosticating the
outcome of mortality but at dissimilar time points (eg, the
Zwolle Risk Score for 30-day mortality vs the Device
Investigation to Lower Late Angioplasty Complications
(CADILLAC) risk score for 6-month mortality).30,31
Together, these methodologic disparities limit the applicability of the scores to subsets of contemporary patients with
AMI-CS and underscore the current uncertainty of when in
the clinical course of AMI treatment currently available CS
risk scores should be applied.
Risk Scores of Patients in Cardiogenic Shock Using
Mechanical Circulatory Support

A limited number of prognostic scores of CS have been
derived from large randomized trials in which CS therapy
varied from standard pharmacologic treatments to the use
of mechanical circulatory support, defined as intra-aortic
balloon pump (IABP) counterpulsation, Impella or venoarterial extracorporeal membrane oxygenation (VAECMO).32 38 (A detailed summary can be found in Supplementary Tables III and IV.)
The most easily recognized of these scores are those
derived from the Should We Emergently Revascularize
Occluded Coronaries for Cardiogenic Shock (SHOCK) trial
and the SHOCK registry cohorts,32 the CardShock study
cohort33 and, most recently, the the Intra-aortic Balloon
Pump in Cardiogenic Shock (IABP-SHOCK) II trial cohort.
All 3 of these scores identified key clinical, historical or
biochemical variables associated with increased in-hospital
mortality in patients with AMI-CS and, uniquely, the scores
were derived from patients in whom early intervention with
the proposed CS therapy was instituted. These scores contrast with others derived from studies in which mechanical
circulatory support was used as salvage therapy.35 38
Current CS Risk Score Limitations

There are several limitations of currently available CSspecific risk scores that warrant mention. The score by
Sleeper et al. derived from the SHOCK trial,8 which identified and tested clinical predictors of short-term outcome,32
is widely regarded as too complex to calculate at the bedside and was developed from a cohort that preceded widespread use of primary PCI. Although contemporary riskstratification tools, including the CardShock33 and IABPSHOCK II34 scores, addressed this ease-of-applicability
limitation, they were derived from data focused exclusively
on patients with AMI-CS. Unsurprisingly, data from a
recent external validation study that compared the CardShock and IABP-SHOCK II scores demonstrated that both
were suboptimal predictors when applied to patients without acute coronary syndrome (CardShock AUC 0.648,
IABP-SHOCK II AUC 0.619, P = 0.31).39 Even the SAVE
and PREDICT VA-ECMO scores, which have been shown
to help predict hospital mortality in patients with CS of
varying etiologies,35,38 may be limited on the therapeutic

end because they do not reflect the recent understanding of
the importance of time-to-support and left ventricular venting in patients’ outcomes.40 42 Accordingly, a need exists
to develop a risk score (or a suite of related scores) that
allow prognostication of CS outcomes independent of the
causes of CS that are easily applied at the bedside and are
derived from a set of patients who were treated by using
contemporary clinical approaches.
A Focus on Variables
In view of the challenges associated with currently available risk scores, clinicians are often required to prognosticate CS outcomes based on clinical acumen. The prognostic
accuracy of this bedside clinical impression may be
improved by focusing on individual patients’ hemodynamic
and biochemical factors that have been identified as being
predictive. These factors are described below and summarized in detail in Supplementary Table V.
The frequency of major predictive variables stratified by
variable type (see below) are depicted in Fig. 1; for all variables across all scores, see Supplementary Fig. I (a–c) and
Supplementary Fig. II.
Age

Age is the most prevalent patient-related risk factor
among published CS prognostic scores27,29,31 35,37,43 53
(Fig. 1). Predictably, the majority of studies from which CS
scores are derived suggest an association between advanced
age and mortality. For example, the GUSTO-1 trial, which
randomized 41,021 STEMI patients to receive 1 of 4 intravenous thrombolytic therapies, demonstrated that age older
than 75 was associated with a 20-fold increase in 30-day
mortality relative to age younger than 45 (P< .0001).49
Similar findings were observed in risk scores introduced in
the primary angioplasty and stent era. In the Primary Angioplasty in Myocardial Infarction (PAMI) risk score, an age
older than 75 years carried an odds ratio (OR) of 7.4 (95%
CI 4.9–11.2) for 6-month mortality vs an OR only of 2.9
(95% CI 1.9–4.5) for ages 65–75 years.30 A similar effect
of age is found in risk scores for patients with AMI-CS
undergoing emergent PCI; in the score proposed by Klein
and colleagues, an OR 2.34 (95% CI 1.68–3.28; P< 0.001)
for in-hospital mortality per 10-year increment beyond age
65 was observed.48 This effect appears to hold in patients
with CS who are treated with mechanical circulatory support (VA ECMO) as well, with age older than 72 years carrying an OR of 2.71 (95% CI 1.22–6.00; P = 0.01) for inhospital mortality.54 Although not from a risk-score study,
these data underscore the adverse effect of advanced age on
CS outcomes, even when high-end CS therapies such as VA
ECMO are used.
Heart Rate

Heart rate (HR), an important physiological parameter
and regulator of total cardiac output, is a component factor
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Fig. 1. Frequency of prognostically important factors across all CS scores. Frequency of all predictive patient, hemodynamic and biochemical factors across all published CS scores, stratified by factor type. Patient factors are in blue, hemodynamic factors are in red and biochemical factorsare in green. ASA, acetylsalicylic acid; BUN, blood urea nitrogen; CABG, coronary artery bypass grafting; CHF, congestive heart
failure; CS, cardiogenic shock; CVA, cerebrovascular accident; DM, diabetes mellitus; FiO2, fraction of inspired oxygen; HLD, hyperlipidemia; HR, heart rate; hr, hour; HTN, hypertension; LBBB, left bundle branch block; LFT, liver function tests; MAP, mean arterial pressure;
PCO2, partial pressure of carbon dioxide; PO2, partial pressure of oxygen; PaO2, partial pressure of arterial oxygen; SBP, systolic blood
pressure; RR, respiratory rate; STE, ST segment elevation; WBC, white blood cells.

in 11 of 22 AMI-CS-related risk scores.27,30,36,46,47,49 53,55
Impaired myocardial contractility caused by ischemia
results in reduced stroke volume, low systemic blood pressure and subsequent essential orthostatic hypotony (EOH).
This reduction in cardiac output simulates an HR increase
as 1 of several compensatory mechanisms to maintain systemic perfusion; tachycardia, however, increases myocardial oxygen demand and, thus, may worsen myocardial
ischemia.56 In the TIMI-STEMI risk score, derived from
14,114 STEMI patients from the InTIME II trial, an HR
greater than 100 beats per minute (bpm) was 1 of the strongest predictors of 30-day mortality (OR 2.3, 95% CI 1.9–
2.8).50 Similar findings were noted in the GRACE risk
score, where a mean HR of 87 bpm was associated with
increased in hospital mortality, with each 10-bpm increase
in HR conferring an OR of 1.2 (95% CI of 1.15–1.24) for
this outcome.47 Overall, incremental increases in HR appear
to carry important prognostic significance in AMI-CS and,
not surprisingly, HR is a predictive variable noted across all
CS prognostic scores (Fig. 1).
Killip Class

Advanced Killip class consistently portends worse clinical outcomes, including the development of CS and
increased short and long-term mortality.3,27,30,31,45,47,49,50,52
In the GUSTO-1 trial, Killip class II vs I and III vs I had

hazard ratios (HRs) of 1.70 (95% CI 1.52–1.90) and 2.95
(95% CI 2.39–3.63) for the development of in-hospital
CS.27 Similarly, in the GRACE registry of 13,708 patients
with acute coronary syndrome, Killip class was among the
8 risk factors most commonly associated with increased inhospital mortality, with each increase in class portending a
2-fold increase in the likelihood of death.47 More recently,
in a secondary analysis of the EPHESUS trial, a 2-fold
increase in sudden cardiac death was observed in patients
with Killip classes III and IV as compared to classes I or
II.57,58
Systolic Blood Pressure

A reduction in SBP may be 1 of the first hemodynamic
parameters to indicate reduced cardiac output and impending CS; it is included in the majority of risk scores for AMICS.27,32,36,46,47,49 52,55,59
A SBP of less than 100 mmHg was associated with
increased likelihood of 30-day mortality (OR 2.7, 95% CI
1.9–3.8) in the Thrombolysis in Myocardial Infarction ST
Elevation Myocardial Infarction (TIMI-STEMI) risk
score.50 Similarly, in the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock
(SHOCK) trial, a mean SBP of less than 85 mmHg was
associated with an increased likelihood of 30-day mortality
(P< 0.001).32 On the other hand, in the CardShock study
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(mean SBP 78 mmHg), this parameter did not independently predict in-hospital mortality (OR 1.03, 95% CI 0.99–
1.06).33 Overall, a reduced SBP appears to be an important
negative prognostic factor in patients with AMI-CS, but the
utility of this parameter may depend on the time-point at
which it is measured and on the presence or absence of inotropes, vasopressors and other therapies that may modify
SBP without treating the underlying causes of CS.

day mortality in the IABP-SHOCK II cohort.34 Unsurprisingly, EOH is also present in multiple risk-scoring systems
and is the second most potent patient-related variable (after
age) that confers poor prognosis.32 35,37,38,53 Notably,
Killip class IV includes EOH as a clinical parameter; hence,
all risk scores in which the Killip classification is present as
a variable necessarily include EOH as an important prognostic variable.3,27,30,31,45,47,49,50,52

Anterior Location of Myocardial Infarction or Left Bundle
Branch Block

Hemodynamic Measurements

Anterior myocardial infarctions place a large volume of
myocardium at risk60 for ischemia and may predispose
patients to adverse outcomes. The Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction
(APEX-AMI) trial, which examined the efficacy of pexelizumab in AMI, demonstrated that anterior MI was associated with an increased likelihood of 30-day mortality (HR
1.45, 95% CI 1.10–1.93).52 Similar results were observed in
the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-1)
trial, which showed that anterior MI portended a 50%
increased 30-day mortality compared to inferior MI (P<
.00001).49 Similarly, left bundle branch block, which generally accompanies more severe clinical presentations of
AMI,61 is predictive of increased short- and long-term mortality in several AMI-CS risk scores.30,32,45,48 50,52
Renal Insufficiency

Chronic kidney disease is among the strongest predictors
of adverse long- and short-term cardiovascular outcomes.
The Controlled Abciximab and Device Investigation to
Lower Late Angioplasty Complications (CADILLAC) trial
(of coronary stenting vs balloon angioplasty in patients with
STEMI but without CS), demonstrated that renal insufficiency (defined as a creatinine clearance of less than 60
mL/min) carried an OR of 5.99 (95% CI 3.83-9.40; P=
0.0001) for 1-year mortality. Furthermore, renal insufficiency was the single strongest predictor of mortality
among the variables studied in this trial.31 Similarly, in the
Intra-aortic Balloon Pump in Cardiogenic Shock (IABPSHOCK II) trial, a creatinine level at admission higher than
1.5 mg/dL was 1 of the 6 independent variables predictive
of increased 30-day mortality with an HR of 1.57 (95% CI
1.17–2.11; P= 0.003).34 Chronic kidney disease has been
identified in multiple AMI-CS risk scores as an important
predictor of poor prognosis.31,32,34,35,37,47,48,52,53
Lactic Acidosis

End-organ hypoperfusion is a common sign of cardiac
failure. In the CardShock trial, a serum lactate greater than
2.0 mmol/L within 6 h from identification of CS, and confusion were both independently associated with increased inhospital mortality.33 Similarly, a lactate level higher than
5.0 mmol/L was predictive of increased likelihood of 30-

Early hemodynamic assessment is a cornerstone of the
therapeutic approach to CS because several hemodynamic
parameters have been identified as strong predictors of inhospital mortality.62 In the SHOCK trial registry of 541
patients with CS, cardiac power output (CPO) and cardiac
power index (CPI; equal to CPO divided by body-surface
area) were the strongest independent hemodynamic parameters of in-hospital mortality. A CPO value of  0.53 Watts
predicted in-hospital mortality with a c-index of 0.69 and
positive and negative predictive values of 59% and 71%,
respectively.63 The inverse correlation between CPI and
mortality has been confirmed in a more contemporary
study64 which, very interestingly, also showed that for a
given CPI, patients with AMI-CS fared much worse than
those with CS in the setting of decompensated chronic heart
failure. This finding may be a reflection of a greater cardiac
power reserve in healthy adults compared to individuals
with chronic heart failure65 and that a low cardiac power
output in patients with AMI-CS indicates that most of the
recruitable reserve available during an acute event has been
exhausted. A substudy of CardShock that examined those
with pulmonary catheters in place was also demonstrative
of the predictive value of early hemodynamic measurements: CI (OR 0.22, 95% 0.09–0.52), CPI (OR 0.347, 95%
0.20–0.60) and stroke-volume index (OR 0.88, 95% 0.82–
0.94) were the strongest predictors of 30-day mortality.66
The pulmonary artery pulsatility index (PAPi) has been
identified as an important hemodynamic indicator of right
ventricular (RV)failure in patients with acute inferior MI
and following left ventricular assist device implantation,
and it independently predicts 6-month mortality or hospitalization in patients with advanced heart failure.67 A PAPi
value of  0.9 carries a specificity of 98.3% and a sensitivity of 100% to predict in-hospital mortality in patients with
inferior MI undergoing emergent PCI.68 By contrast, a
PAPi value of < 1.85 predicts RV failure after isolated left
ventricular assist device implantation with 94% sensitivity
and 81% specificity.69 As our understanding of cardiogenic
shock evolves to recognize the importance of the RV, the
full role of RV function in CS outcomes and in the identification of patients who may benefit from advanced RV support strategies is further defined below.
More recently, mean right arterial pressure has been identified as another sensitive hemodynamic marker in CS. A
retrospective study of 545 patients with CS found right arterial pressure  14 mmHg to be associated with higher
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mortality rates and end-organ dysfunction as identified by
elevated lactate, creatinine, liver enzymes, and pulmonary
capillary wedge pressure.70
Left ventricular end diastolic pressure (LVEDP) is an
indirect measure of wall tension and is, therefore, related to
myocardial oxygen consumption. LVEDP is also closely
correlated with pulmonary capillary wedge pressure and,
thus, provides an index of lung congestion. In the Pexelizumab in Conjunction With Angioplasty in Acute Myocardial
Infarction (APEX-AMI) study, an LVEDP greater than 22
mmHg was associated with higher rates of CS (4.6% vs
1.7%; P< 0.001) and death (4.1% vs 2.2%; P= 0.014) at
90 days. Furthermore, for the composite of death, CS, or
congestive heart failure within first 2 days, a hazard ratio of
1.4 per 5 mmHg increase in LVEDP was conferred (95%
CI 1.23–1.59; P< 0.001) compared to those with lower LV
filling pressures.71 The utility of this parameter was refined
by Sola et al. in a retrospective analysis of 219 consecutive
patients with STEMI, in which the introduction of a ratio of
SBP to LVEDP better predicted 30-day mortality when
compared to LVEDP alone.72 An SBP/LVEDP ratio of less
than 4 defined an increased risk of in-hospital death (32%
vs 5.3%; P < 0.001) and IABP usage (51.6% vs 9.6%; P<
0.0001); the AUC of SBP/LVEDP was also superior to that
of LVEDP alone for the prediction of in-hospital mortality
(0.69 vs 0.61; P= 0.04).72
Overall, hemodynamic assessment appears to improve
CS prognostication, and patients with CS should be considered for early invasive hemodynamics with right heart catheterization.62 This assessment may provide vital
information to guide the need for advanced therapies (eg,
mechanical circulatory support [MCS]). Although past studies failed to show a survival benefit of invasive hemodynamic monitoring using a pulmonary artery catheter
(PAC),73 75 several limitations in these data have been
identified, including an effect of procedural volume on
PAC catheter usage and variability in right heart catheterization interpretation skills.62,76 Furthermore, a recent observational, single-center study has recently challenged
previous data by demonstrating a reduction in all-cause
death in AMI-CS with the use of hemodynamic (PAC)
monitoring in selected patients.77
Biochemical Factors

In recent years, mounting evidence has suggested that the
systemic inflammatory response is an important late mediator in CS. Release of inflammatory substances, expression
of nitric oxide and inappropriate peripheral vasodilation
lead to a reduction in systemic vascular resistance and, in
turn, to increased vasopressor requirements.78 81 Approximately 18% of patients with AMI-CS develop a systemic
inflammatory response, and multiple studies have evaluated
the significance of inflammatory markers in this patient subset.
N-terminal-pro-B-type natriuretic peptide (Nt-proBNP),
interleukin 6 (IL-6) and procalcitonin (PCT) levels have

also been investigated as possible prognostic discriminators
in CS. In a prospective single-center study consisting of 87
patients with AMI-CS treated with revascularization and
IABP, an IL-6 level of 307 pg/mL on admission had a
57.1% sensitivity and a 97.7% specificity for predicting 30day mortality (P< 0.05). In the same study, PCT levels of
1.23 ug/L at 24 hours and 0.71 ug/L at 72 hours carried
high sensitivity (83.3% and 90.0%) and specificity (81.4%
and 82.9%) for 30-day mortality.82 Recently, PCT was further evaluated in a prospective, single-center study of 102
patients with STEMI undergoing primary PCI or thrombolysis. A PCT level higher than 1.5 ng/mL was significantly
associated with CS, and a level higher than 0.2616 ng/mL
had 85.7% sensitivity and 78% specificity in predicting 30day mortality (P= 0.006)83; notably, however, these data
have yet to be subjected to peer review.
Finally, NT-proBNP levels higher than 12,782 pg/mL
have also been identified as an important marker of 30-day
mortality in CS patients in univariate and multivariate survival analyses (P< 0.001).84 In this 2009 study by Jarai et
al., patients with CS and a combination of NT-proBNP >
12,782 pg/mL and IL-6 level >195 pg/mL had significantly
higher likelihood of 30-day mortality than those with lower
IL-6 and NT-pro BNP levels (93.7% vs 26.3% 30-day mortality). In support of these findings, a more elevated NTproBNP level was also observed in nonsurvivors compared
to survivors in the IABP-SHOCK trial (NT-proBNP 14,370
§ 4886 pg/mL vs 4590 § 1230 pg/mL; P< 0.05).85 Of
note, although Nt-proBNP levels are inversely related to
short-term survival in patients with CS, this may be due to
its association with renal dysfunction, which is known to
predict mortality in AMI-CS independently.86
Recently a novel biochemical risk score has been derived
from the randomized CULPRIT-SHOCK trial population.87
Using a robust approach of derivation, internal-external
(temporal) validation and external validation against the
IABP-SHOCK II trial participants, Ceglark and colleagues
derived the CLIP (Cystatin C, Lactate, Interleukin-6 and
NT-proBNP) score to predict the probability of 30-day mortality from AMI-CS in the CULPRIT-SHOCK trial group.
This score, derived from 58 candidate variables that were
distilled to 4 well-established, predictive biomarkers carries
a high predictive value, with a c-statistic of 0.82 in both
internal and internal-external validation and 0.73 in external
validation. Uniquely, this score applies only objective, measurable variables and avoids the use of characteristics
dependent on bedside clinical assessment, which may be
subject to inter-rater variability due to clinical assessment
acumen. Though the potential for measurement bias was
acknowledged by the authors as a potential limitation of
their study, the CLIP score represents an important advance
in the use of biochemical markers in the short-term prognostication of AIM-CS. Notably, however, the utility of this
score in patients with chronic heart failure and with CS,
whose biochemical milieus may differ substantially from
those of patients with AMI-CS due to the acute-on-chronic
nature of their disease process, has yet to be established.
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Further, because biochemical variables-based scores, particularly when applied at presentation, are limited to prognostication very early in the clinical course, they may not
adequately represent the impact of therapies instituted in a
timely fashion; this is particularly true for therapies that
were not used systematically in the the cohort from which
these scores were derived (eg, contemporary percutaneous
MCS devices). Ultimately, the CLIP score does, however,
firmly establish the combination of its component variables
as powerful markers that justify further study in other
cohorts and at other time points in the clinical course of CS.
At present, many novel biochemical markers are under
investigation and may be effective in aiding the prognostication of AMI-CS; however, the data to support their routine use have not yet been established. For a detailed review
of both novel and established biomarkers in CS, see work
by Iborra-Egea and colleagues.88
The Future of CS Risk Scores: Clinical Utility and
Development
At least 3 key questions arise in light of the historical
account of CS risk scores. First, what is the clinical utility
of such scores? Second, do available scores fulfill the needs
of clinicians and clinical trialists, or are new scores needed?
And finally, what are the characteristics of an ideal new risk
score (or set of scores), and how should they be developed?
Clinical Utility

Clinically, CS scores can serve at least 2 important purposes, both related to risk stratification. In clinical practice,
a cluster of tightly linked, hotly debated questions revolve
around who will benefit from aggressive therapeutic interventions, ranging from invasive hemodynamic monitoring
in an intensive care setting to the use of advanced MCS
devices. Thus, in very practical terms, such scores would
ideally inform clinical decision making. Some early retrospective studies have started to address these questions. For
example, after stratifying patients with CS who received
Impella support (n = 166) into low-risk (n = 19), intermediate-risk (n = 72) or high-risk (n = 75) of mortality based on
their CardShock scores at the time of presentation, Schafer
et al. demonstrated that only patients in the high-risk group
had a significantly lower-than-predicted mortality rate.89
Extrapolating conceptually, a prospectively validated score
to identify patients who are most likely to benefit from
MCS would offer great value to clinicians.
The second, related application of a risk score is in the
context of clinical trials of CS therapies, such as MCS.
Analogous to clinical practice, enrollment in a clinical trial
should be enriched with patients most likely to benefit from
the therapy. A contemporary counterexample is the Impella
vs IABP Reduces Mortality in STEMI Patients Treated
with Primary PCI in Severe Cardiogenic Shock (IMPRESS)
study, in which 44 of the 48 patients enrolled had experienced cardiac arrest with > 20 minutes until return of spontaneous circulation and had serum lactate levels >

7.5 mmol/L by the time of enrollment.13 Although the mortality rate in this (underpowered) study was in the range of
other contemporary trials in this setting, nearly a quarter of
patients in both arms died as a result of anoxic brain injury;
this may have contributed to the trial’s primary finding,
which was a lack of benefit of Impella over IABP in patients
with AMI-CS. Use of a score that would exclude such highrisk patients with little chance of survival would be highly
advantageous for studies aimed at studying treatments for
CS.
Is it Time For New Scores?

Given that 30 scores have appeared in the literature over
the past > 50 years, none of which is widely used at the
bedside, one can simultaneously surmise that, at present,
there is no available risk score that optimally addresses current needs, and that any new score would required a novel
approach if it were to prove useful.
To illustrate the current state of the art and identify
potential voids, one may consider the characteristics of 4
scores that have received recent attention in the literature:
the CardShock risk score (6 components); the IABPSHOCK II risk score (6 components); the Inova CS risk
score (7 components); and the SCAI staging system (no
specific number of components). The IABP-SHOCK II
score applies specifically to patients with AMI, whereas the
Inova, CardShock and SCAI have been applied to other
forms of shock as well.
CardShock has been well validated39 and can be estimated at the time of presentation, with only its need for precise/accurate LVEF introducing a short time delay (due to
the limited accuracy of emergency department point-ofcare ultrasound for this determination90). One limitation of
CardShock is that, by design, it assesses risk of only shortterm (14-day) mortality, though 1 recent analysis did demonstrate its ability to predict 30-day mortality.89
The IABP-SHOCK II score includes glucose, arterial lactate and creatinine, the last of which is not immediately
available at presentation, therefore precluding its immediate
use. Further, this score is designed specifically for patients
with AMI who will undergo rapid percutaneous revascularization, given its reliance on postintervention TIMI flow.
The Inova score requires invasive hemodynamics and
components that can evolve over the time of the hospital
admission and as therapies are applied, such as lactate,
CPO, PAPi, and the need for renal replacement therapy also
precluding its immediate application. Additionally, this
score has yet to be validated.
The SCAI classification system, which contains a cardiac
arrest modifier (given the negative effect of cardiac arrest
on clinical outcome), has very limited validation. Retrospective analyses based on the entirety of a patient’s hospitalization have correlated with increasing SCAI stage and
with increased risk of mortality,15,91 but these studies are
limited by methodological considerations, including their
retrospective designs and subjective initial identification of
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CS patients. When applied prospectively, increasing SCAI
stage does appear to correlate with worsening survival at 1
year, as do changes in the SCAI stage when the classification is reapplied 24 hours after admission.92 However,
unlike other scores, the SCAI classification does not actually give an initial estimate of mortality. Thus, although the
SCAI stages may be helpful in communicating the severity
of current clinical status (1 of the initial goals of its development4), it remains to be determined how this system may
be used most effectively to prognosticate during lengthy
hospitalizations and in clinical trials.
It is, therefore, obvious that each of these scores fills a
different niche; not a single 1 of these scores (nor any other
score reviewed above) serves all clinical practice or trial
needs. Accordingly, a novel suite of scores may be more
appropriate, across which key component variables are similar but can be adjusted with modifiers to gear applicability
toward a particular cause of CS. (See Supplementary Table
VI for a summary of advantages and limitations of several
major scores.)

scores derived from trials of AMI-CS that consider more
dramatic features, such as altered mentation or grossly elevated lactate levels, may fail to capture this group. Given
the dynamic, complex and multiphenotypical nature of CS,
an “ideal risk score” might be applied using universally
available metrics at presentation, such as heart rate, blood
pressure or other physical examination findings, and reapplied later during hospitalization using additional data to
refine its prognostic estimates. Such as score could thus
take both initial impressions and advanced metrics (eg,
invasive hemodynamics) into consideration, as well as the
response to initial therapeutic measures. Further, novel
scores may also add variables that have not been captured
in previous scores or may become available later in a
patient’s clinical course; the presence of important peripheral vascular disease, and recent use of negative inotropic
agents or anticoagulants are examples of such variables; all
of them may affect the safety with which emergency procedures (eg, MCS implantation) may be provided.
How Should New Scores, if Needed, Be Developed?

The Ideal Score

Naturally, scores must be contemporary to reflect
improvements in standards of clinical care over time and
must be applicable to specific subgroups of patients (eg,
those with STEMI, those with acute chronic heart failure,
those placed on ECMO, etc.). Perhaps more critically, however, scores must carefully consider the nature of a disease
process, including how it may evolve over time. For example, scores derived primarily from trials of acute forms of
CS, such as AMI, may not sufficiently consider the neurohormonal compensatory responses (eg, chronically elevated
NT-proBNP levels) typical of patients with chronic heart
failure who also compose an important component of the
population with CS. Furthermore, patients with chronic
heart failure presenting with CS may do so more subtly,
requiring invasive hemodynamics to make the diagnosis;

Historically, with each major interventional trial in CS, a
new risk score is generated that aims to consider not only
the unique aspects of the trial patient population but, in
some instances, the effects of a novel therapy (Fig. 2).
There would be great clinical use for a single validated risk
score to inform clinical care and guide inclusion of patients
in clinical trials, but history suggests that this may be unrealistic. Rather, customized scores for specific applications
may be more appropriate.
However, one can question the use of randomized-trial
populations to derive instruments that are intended for wide
applicability; this approach seems to be fundamentally at
odds with the principles of randomized-trial design, which
foster the identification of a very specific patient subset
upon which to test a hypothesis. Scores generated using this
strategy may not be generally applicable. An additional

Fig. 2. Timeline of cardiogenic shock trials and risk score development over 3 major therapeutic eras: pre-reperfusion, primary PCI,
mechanical circulatory support.
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consideration is that, as highlighted above, some risk scores
rely on factors determined prior to treatment, whereas
others rely on factors available only after therapies have
been instituted. This variability reflects the real-world
diversity of CS etiologies, the availability of advanced therapies and the variability of bedside decision making.
Based on these considerations, we suggest that risk
scores would best be generated by large, well-conducted,
real-world CS registries that include a broad range of
patients and treatments and into which enrollment is
consecutive and audited against comprehensive national
or international outcome databases (eg, the US National
Cardiovascular Data Registry) to avoid enrollment
biases. In general, the most useful scores would be easy
to calculate at the bedside, both at initial presentation
and subsequently during hospitalization, to account for
the effects of therapy. Further, these scores would be
based on factors that can be determined rapidly by using
bedside examination and readily available testing. Interestingly, 4 of the 5 most frequently encountered and
prognostically valuable factors are easily identifiable at
first medical contact: age, systolic or mean arterial blood
pressure, heart rate, the presence of heart failure, and
mental status (Fig. 1). These factors have already been
shown across multiple scores and patient populations to
predict outcomes effectively, so they may represent a
suitable starting point.
Another potentially important opportunity relates to futility. The focus of score development has been on predicting
risk of developing or surviving CS, but an alternative and as
yet unexplored concept is the potential utility of a “futility
score,” a score that rapidly and accurately identifies patients
who will almost certainly not survive, regardless of CS
treatment. Such a score would be strongly relevant, given
an aging population with increasing comorbidity burdens93
and rising survivorship of out-of-hospital cardiac
arrest.94 An ideal futility score would include only
parameters that are immediately available upon presentation (eg, age, blood pressure, heart rate, time to return of
spontaneous circulation, pH and lactate levels), be easily
applied at first medical contact and, of course, be perfectly sensitive and specific. Such a score would not
only allow clinicians to focus precious health care
resources on patients who are most likely to benefit but
would also allow early palliative-care consultations and
facilitate honest and informed prognostic discussions
with the family members of patients whose prognoses
are grim. Finally, such a score may also help focus subsequent randomized trials by excluding patients unlikely
to benefit from the therapeutic interventions being
tested. As described in the example above in relation to
the IMPRESS study, patients with irreversible brain
injury and advanced multiorgan failure could be
excluded from clinical trials rapidly.
A representation of the 3 major therapeutic eras in the
management of cardiogenic shock, overlaid with the publication of critical trials in CS management and currently

available risk scores to illustrate the timeline of risk score
development and clustering around the publication of major
CS trials.
Conclusions
There are multiple risk-prediction models for patients
presenting with CS and/or at risk for developing CS. However, a scoring system that is capable of early prognostication to inform therapeutic decisions in clinical practice is
still needed. An all-encompassing risk score that predicts
outcomes at multiple time points and in multiple clinical
scenarios may be unrealistic and is unlikely to be developed
from randomized trial data, given the selective nature of
patients enrolled in these studies. Rather, it may be preferable to use large, carefully executed real-world registries for
the development of such scores. Furthermore, therapeutic
focus may be sharpened by the development of a futility
score that predicts likely failure early in a patient’s clinical
course. In the current era, as focus on CS epidemiology,
pathophysiology and therapeutics intensifies, it is important
to refine the prognostication of CS outcomes to optimize
both clinical practice and enrollment in clinical trials. The
insights gained from the current review of the history of CS
risk scores delineates the current state of knowledge, highlights gaps in our understanding and provides perspectives
on the path forward.
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